-+ 0.00%
-+ 0.00%
-+ 0.00%

Medicenna Completes Enrollment in Phase 1/2 MDNA11 Cancer Trial With 152 Patients

PUBT·11/04/2026 12:09:11
Medicenna Completes Enrollment in Phase 1/2 MDNA11 Cancer Trial With 152 Patients
  • Medicenna Therapeutics completed enrollment in its global Phase 1/2 ABILITY-1 cancer study of MDNA11, enrolling 152 patients.
  • The trial evaluates MDNA11 alone or in combination with Merck's Keytruda.
  • Updated results will be presented at the Society for Immunotherapy of Cancer annual meeting on November 7, 2026.
  • A November 10, 2026, webinar will discuss the findings with clinical experts.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Medicenna Therapeutics Corp. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202611040700PRIMZONECNPR____9869968) on November 04, 2026, and is solely responsible for the information contained therein.